FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer

November 18, 2022 11:51 am

by Jason Harris

The FDA has asked Clovis Oncology to limit use of rucaparib (Rubraca) to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.1

fdaThe company is considering the FDA’s request. If the 2 sides

Read more

FDA Requests Restriction of Second-line Maintenance Niraparib Indication in Ovarian Cancer

November 14, 2022 11:41 am

by Kristi Rosa

At the request of the FDA, GlaxoSmithKline (GSK) plc will restrict the second-line maintenance indication for niraparib (Zejula) to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA

Read more

Mirvetuximab Soravtansine Generates Improvement in PROs Vs Chemotherapy in Advanced Ovarian Cancer

October 13, 2022 2:03 pm

by Chris Ryan

Treatment with mirvetuximab soravtansine elicited a statistically significant benefit vs investigator’s choice of chemotherapy for the OV28 abdominal/gastrointestinal symptom subscale in patients with folate receptor alpha–positive, advanced ovarian cancer.

Treatment with mirvetuximab soravtansine elicited a statistically significant

Read more

Elizabeth Swisher, MD, on Predicting Therapy Benefits in Ovarian Cancer

October 5, 2022 4:42 pm

by Mark L. Fuerst

– KELIM score can now be used to look at upfront response, study showed

Tumor primary chemosensitivity testing can help determine if ovarian cancer patients need a boost along with first-line chemotherapy. In the VELIA trial, … Read more

Nonselective Beta-Blockers May Improve Outcomes in Ovarian Cancer

August 29, 2022 2:19 pm

by Charles Bankhead

Women with cardiovascular conditions (CVCs) and ovarian cancer had better 2-year survival if they received a nonselective beta blocker (NSBB) at or around the time of cancer surgery, a review of medical records showed.

Two-year postoperative survival … Read more

DS-6000a Displays Early Clinical Activity in Ovarian Cancer and RCC

August 24, 2022 2:20 pm

In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.

Interim data from a … Read more

Cure Rate After Chemotherapy in Stage III Ovarian Cancer

July 27, 2022 11:09 am

by Vicki Moore, PhD

Researchers found that 18% of patients with advanced ovarian cancer remained disease-free for at least 10 years after receiving chemotherapy and were likely cured. The team detailed their findings in Gynecologic Oncology.

To determine what … Read more

ADCs Begin to Carve a Place in the Treatment Landscape for Ovarian Cancer

July 26, 2022 2:39 pm

by Brittany Lovely

Patients with recurrent, platinum-resistant ovarian cancer have limited effective treatment options available, but a class of targeted antibody-drug conjugates (ADCs) represent a promising development for this population.1

The treatment landscape for patients who experience disease progression

Read more

Epigenetic ‘Priming’ Boosts Cancer Immunotherapy

July 25, 2022 11:11 am

by Will Doss

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, making them more suitable for treatment with immunotherapy, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

This could … Read more

ASCO, ACCC Issue Recommendations to Boost Clinical Trial Diversity

July 24, 2022 10:44 am

by Jason Harris

The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) have issued a joint statement outlining 6 recommendations for boosting participation among underserved communities.1

Increasing the racial and ethnic diversity in

Read more

Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer

July 20, 2022 12:09 pm

by Caroline Seymour

The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the Read more

Farletuzumab Ecteribulin Shows Early Activity in Platinum-Resistant Ovarian Cancer

June 21, 2022 11:03 am

by Chris Ryan

The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer.

The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in

Read more

Neoadjuvant Abemaciclib and Fulvestrant Facilitates High Complete Gross Resection Rate in Low-Grade Serous Cancer

June 15, 2022 12:04 pm

by Caroline Seymour

The combination of abemaciclib and fulvestrant led to encouraging responses when used as neoadjuvant therapy which translated to high complete gross resection rates in patients with advanced, low-grade serous ovarian, fallopian tube, and peritoneal carcinoma.

The combination

Read more

MD Anderson Researchers Present Encouraging Results of Early-Stage Clinical Trials at 2022 ASCO Annual Meeting

June 7, 2022 10:45 am

by University of Texas M.D. Anderson Cancer Center

Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more

Frontline Bevacizumab Beneficial for Ovarian Clear Cell Carcinoma, Retrospective Analysis Shows

June 6, 2022 9:49 am

by Lisa Astor

Bevacizumab improved progression-free survival and overall survival when added to frontline chemotherapy in patients with advanced ovarian clear cell carcinoma, according to a retrospective analysis of patients treated in Japan from 2008 to 2018.

A retrospective analysis

Read more

Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer

April 27, 2022 12:40 pm

by Matthew Stenger

In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in … Read more

Olaparib Dosage Can Be Reduced Without Affecting Survival in Ovarian Cancer

April 18, 2022 12:28 pm

by Lindsay Fischer

New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.

Patients with BRCA1/–mutated, platinum-sensitive, recurrent ovarian cancer who needed to reduce

Read more

Relacorilant/Nab-Paclitaxel Combo Improves OS in Recurrent, Platinum-Resistant Ovarian Cancer

April 5, 2022 11:17 am

by Kristi Rosa

The addition of relacorilant to nab-paclitaxel improved overall survival compared with nab-paclitaxel alone in patients with recurrent, platinum-resistant ovarian cancer.

The addition of relacorilant to nab-paclitaxel (Abraxane) improved overall survival (OS) compared with nab-paclitaxel alone in patients

Read more

Maintenance Rucaparib Significantly Improves PFS in Phase 3 ATHENA-MONO Trial for Advanced Ovarian Cancer

March 31, 2022 10:44 am

by Ariana Pelosci

A significant improvement in progression-free survival was observed in the phase 3 ATHENA-MONO trial with first-line maintenance rucaparib vs placebo in patients with advanced ovarian cancer.

Progression-free survival (PFS) was significantly improved with first-line rucaparib (Rubraca) as

Read more

Ovarian Cancer Patients in PARP Inhibitor Trials Don’t Reflect Real-World Population

February 25, 2022 11:33 am

by Jonathan Goodman, MPhil

Hispanic and Non-Hispanic Black patients were significantly underrepresented, but Asian/Pacific Islander patients were overrepresented.

Clinical trials of PARP inhibitors in patients with ovarian cancer do not accurately reflect the racial and ethnic makeup of the real-world … Read more